Isha Bangia, PharmD, MBA

Isha Bangia, PharmD, MBA, is a manager of US market access at Certara Evidence & Access. She received her PharmD from Rutgers University and an MBA from Johns Hopkins University. Her current responsibilities include optimizing product value stories and working with customers to improve access across the US healthcare system. Her experience includes practicing pharmacy, payer market research, and pharma strategy and analytics. Her work has covered many therapeutic areas, including biosimilars, oncology, diabetes, vaccines, and rare diseases.
Biosimilar discounts to reference products have improved over time, but they are deeper in some categories than others.
Jun 9, 2020 @06:19 PM
Based on the number of bills coming through Congress, it is clear that biosimilars have become synonymous with decreasing healthcare costs. Even with only a few biosimilars commercially available thus far, the federal push towards these drugs has been pronounced.
Nov 25, 2019 @01:39 PM
There remain many uncertainties and questions around the success of these agents. It is therefore critical for sponsors and other stakeholders to consider some of the potential hurdles and policy shifts facing anticancer biosimilar uptake and ultimately reimbursement in the United States.
Aug 9, 2019 @12:17 PM
Employers have long been a silent stakeholder in the healthcare system.
Feb 14, 2019 @02:52 PM
The sluggish acceptance of biosimilars in the United States has often been compared to that of the European Union, where biosimilars took a more accelerated course. When looking at the United States, however, one cannot overlook a key difference between its healthcare structure and that of many other countries: payers.
Dec 14, 2018 @02:35 PM

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.